| BSA |
Body surface area |
| CR |
Complete response |
| CTCAE |
Common Terminology Criteria for Adverse Events |
| ctDNA |
Circulating tumor DNA |
| DLT |
Dose limiting toxicity |
| EFS |
Event free survival |
| EKG |
Electrocardiogram |
| EWS |
Ewing sarcoma |
| IV |
Intravascular |
| MTD |
Maximum tolerated dose |
| mTKI |
multitargeted kinase inhibitors |
| PR |
Partial response |
| RECIST |
Response Evaluation Criteria in Solid Tumors |
| RP2D |
recommended phase 2 dose |
| RTK |
Receptor tyrosine kinase |
| SD |
Stable disease |
| TRAE |
treatment related adverse effect |
| VEGFR-2 |
vascular endothelial growth factor receptor 2 |
| ULP-WGS |
ultra-low passage whole genome sequencing |
| UPC |
urine protein/creatinine |